EP0721467B1 - Use of relaxin as an analgesic and palliative for intractable pain - Google Patents
Use of relaxin as an analgesic and palliative for intractable pain Download PDFInfo
- Publication number
- EP0721467B1 EP0721467B1 EP94930479A EP94930479A EP0721467B1 EP 0721467 B1 EP0721467 B1 EP 0721467B1 EP 94930479 A EP94930479 A EP 94930479A EP 94930479 A EP94930479 A EP 94930479A EP 0721467 B1 EP0721467 B1 EP 0721467B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pain
- relaxin
- palliative
- mammal
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
Definitions
- This invention relates to the use of relaxin to reduce pain.
- Relaxin is a peptide hormone primarily synthesized by the theca interna cells of the corpus luteum during pregnancy. It may also be synthesized in small amounts by the human uterus and placenta. It is known to cause relaxation of the pubic symphysis prior to parturition.
- the invention also features the use of relaxin in the manufacture of a medicament for the treatment of pain.
- the pain is chronic; and the pain results from stretching, swelling, or dislocation of a tissue of the mammal (for example, chronic back pain, tumor pain, iatrogenic pain, arthritic joint pain, or postpartum pelvic joint pain).
- relaxin may be used generally as an analgesic and palliative for pain
- the conditions most amenable to its therapeutic administration are those in which unusual stress is chronically placed on tissues because of an acquired or inherent malformation which results in the displacement of tissues from their natural disposition in the body.
- Relaxin finds utility, for example, in the treatment of severe chronic pain, particularly pain arising from stretching, swelling, or dislocation of tissues.
- a partial list of preferred therapeutic indications follows; this list is provided to illustrate, not limit, the invention.
- Chronic back pain is generally due to one or more of the following six causes: (i) stress on intervertebral facet joints, caused by slippage, arthritis, wedging, or scoliosis; (ii) radiculopathy, the mechanical compression of the nerve root due to bulging discs or tumors; (iii) tendonitis or tendon sprain; (iv) muscle spasm or muscle sprain; (v) ischemia, a local insufficiency in circulatory flow; and (vi) neuropathy, damage to nervous tissue of metabolic etiology or arising from cord tumors or central nervous system disease. The first four of these causes of chronic back pain account for the great majority of cases, all of which are amenable to relaxin therapy.
- the local unrestricted proliferation of cells in cancer leads to pain when the displaced tissues are subjected to the mechanical stress required to accommodate the increased volume occupied by the tumor mass. This pain has as its underlying cause the severe local stretching of tissues by the neoplastic lesion.
- the tumor burden is confined to a small enclosed compartment, such as the marrow of a bone, the resulting pressure can result in severe pain which can be very difficult to manage clinically.
- Use of relaxin in the management of tumor pain will prove a valuable adjunct to more conventional, opioid-based therapies.
- relaxin may be administered systemically, for example, formulated in a pharmaceutically-acceptable buffer such as physiological saline.
- a pharmaceutically-acceptable buffer such as physiological saline.
- routes of administration include, for example, subcutaneous, intramuscular, or intradermal injections which provide continuous, sustained levels of the drug in the patient.
- relaxin may be given to a patient by injection of a slow release preparation, slowly dissociating polymeric form, or crystalline form; this sort of sustained administration may follow an initial delivery of the drug by more conventional routes (for example, those described above).
- relaxin may be administered using an infusion pump, thus allowing a precise degree of control over the rate of drug release, or through instillation of relaxin in the nasal passages in a similar fashion to that used to promote absorption of insulin.
- relaxin may be delivered by aerosol deposition of a powder or solution into the lungs.
- Relaxin may also be administered locally to achieve substantial palliative outcomes. Since the desired action of the agent is generally upon a circumscribed mass of tissue proximate to a specific stress, delivery of the hormone by means which promote high local concentrations in the vicinity of the stress may be especially desirable. For this reason injection of the agent into tissue sites adjacent to, or upstream of the draining circulation of the affected site will, where possible, be preferable. Alternatively, in conditions involving deep organ structures, for example in the displacement of tissue by invasive tumors, implantation near the affected site of sustained release formulations of relaxin (such as osmotic pumps or erodable polymeric compositions impregnated with the hormone) may be preferred.
- sustained release formulations of relaxin such as osmotic pumps or erodable polymeric compositions impregnated with the hormone
- Relaxin for either systemic or local administration, may be obtained from any commercially available source (e.g., Genentech, Inc., South San Francisco, CA) or may be synthesized either by standard techniques of recombinant polypeptide production (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989; Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1989) or by peptide synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984 The Pierce Chemical Co., Rockford, IL).
- any commercially available source e.g., Genentech, Inc., South San Francisco, CA
- peptide synthesis e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984 The Pierce Chemical Co., Rockford, IL
- Relaxin gene and peptide sequences are provided, e.g., in Hudson et al., Nature 301:628, 1983; Hudson et al., EMBO J. 3:2333, 1984; and Bryant-Greenwood, Molecular and Cellular Endocrinology 79:C125, 1991.
- relaxin polypeptide native to a species will be preferred for therapeutic administration.
- relaxin fragments or analogs shown to be functional e.g., in the bioassays of Fei et al. (Biochem. Biophys. Res. Comm. 170:214-222, 1990) and Kramer et al. (In Vitro Cell. Dev. Biol. 26:647-656, 1990) are also useful in the invention.
- Particularly preferred relaxin fragments include the B29 relaxin fragment described by Winslow et al. (Proc. 71st Meeting of Endocrine Society 889 Abstract, 1989) and Bryant-Greenwood ( supra ).
- Particularly preferred relaxin analogs include polypeptides which differ from a native relaxin polypeptide only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, aspartic acid for glutamic acid, etc.).
- Other preferred analogs include relaxin polypeptides which are modified for the purpose of increasing peptide stability; such analogs may contain, e.g., one or more desaturated peptide bonds or D-amino acids in the peptide sequence or may be formulated as cyclized peptide molecules.
- a prorelaxin polypeptide see, e.g., Hudson et al., EMBO J. 3:2333, 1984; and Vu et al., Life Sci. 52:1055, 1993 may be administered as an analgesic and palliative for pain according to the invention.
- Relaxin is administered systemically at a dosage that provides reduction in pain, typically between 0.1-1.6 nanogram/ml and preferably 0.7 nanogram/ml. Where local administration schemes are employed, the concentrations of relaxin in the affected tissue may substantially exceed these levels.
- administering may promote loosening of connective tissues, it may be desirable, where possible, to encourage muscular development through physical therapy to counteract any excessive loosening observed during the course of relaxin treatment.
- the methods of the invention may be used to reduce the disorders described herein in any mammal, for example, humans, domestic pets, or livestock.
- the relaxin employed is preferably specific for that species (see, e.g., Haley et al., DNA 1:155, 1982).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (9)
- Use of relaxin in the manufacture of a medicament for the treatment of pain in a mammal.
- The use of claim 1, wherein said pain is chronic.
- The use of claim 1 or 2, wherein said pain results from stretching, swelling, or dislocation of a tissue of said mammal.
- The use of claim 1, 2 or 3, wherein said pain is chronic back pain.
- The use of claim 1, 2 or 3, wherein said paint is tumor pain.
- The use of claim 1, 2 or 3, wherein said pain is iatrogenic pain.
- The use of claim 1, 2 or 3, wherein said pain is arthritic joint pain.
- The use of claim 1, 2 or 3, wherein said pain is postpartum pelvic joint pain.
- The use according to any one of claims 1 to 8, wherein said mammal is a human.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US128912 | 1993-09-29 | ||
US08/128,912 US5656592A (en) | 1993-09-29 | 1993-09-29 | Use of relaxin as an analgesic and palliative for intractable pain |
PCT/US1994/010867 WO1995009184A1 (en) | 1993-09-29 | 1994-09-26 | Use of relaxin as an analgesic and palliative for intractable pain |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0721467A1 EP0721467A1 (en) | 1996-07-17 |
EP0721467A4 EP0721467A4 (en) | 1998-04-22 |
EP0721467B1 true EP0721467B1 (en) | 2002-01-16 |
Family
ID=22437587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94930479A Expired - Lifetime EP0721467B1 (en) | 1993-09-29 | 1994-09-26 | Use of relaxin as an analgesic and palliative for intractable pain |
Country Status (10)
Country | Link |
---|---|
US (1) | US5656592A (en) |
EP (1) | EP0721467B1 (en) |
JP (1) | JPH09503208A (en) |
KR (1) | KR960704933A (en) |
AT (1) | ATE211920T1 (en) |
AU (1) | AU7958694A (en) |
DE (2) | DE721467T1 (en) |
ES (1) | ES2097100T3 (en) |
PT (1) | PT721467E (en) |
WO (1) | WO1995009184A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0675732B1 (en) * | 1993-07-27 | 2006-06-28 | Mario Bigazzi | Use of relaxin in the manufacture of therapeutic agents |
US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
WO1999040929A1 (en) * | 1998-02-12 | 1999-08-19 | The General Hospital Corporation | Methods to potentiate cancer therapies |
US6719977B1 (en) | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
CN1158636C (en) | 1998-08-14 | 2004-07-21 | 3M创新有限公司 | Applications for radio frequency identification systems |
DE69938671D1 (en) | 1998-08-14 | 2008-06-19 | 3M Innovative Properties Co | APPLICATIONS FOR RF IDENTIFICATION SYSTEMS |
US6251863B1 (en) | 1998-09-08 | 2001-06-26 | Samuel K. Yue | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
US6984128B2 (en) * | 2002-11-01 | 2006-01-10 | Bas Medical, Inc. | Methods for enabling and stabilizing tooth movement |
CN104888182A (en) * | 2015-07-07 | 2015-09-09 | 韩军 | Traditional Chinese medicine preparation for treating postpartum abdominal pain and preparation method therefor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656249A (en) * | 1982-06-10 | 1987-04-07 | Howard Florey Institute Of Experimental Physiology And Medicine | Peptides with relaxin activity |
US5145962A (en) * | 1982-08-12 | 1992-09-08 | Howard Florey Institute Of Experimental Physiology And Medicine | Human pro relaxin polypeptides |
US5179195A (en) * | 1982-12-13 | 1993-01-12 | Howard Florey Institute Of Experimental Physiology And Medicine | Human relaxin polypeptides |
-
1993
- 1993-09-29 US US08/128,912 patent/US5656592A/en not_active Expired - Lifetime
-
1994
- 1994-09-26 JP JP7510392A patent/JPH09503208A/en active Pending
- 1994-09-26 KR KR1019960701447A patent/KR960704933A/en not_active Application Discontinuation
- 1994-09-26 DE DE0721467T patent/DE721467T1/en active Pending
- 1994-09-26 PT PT94930479T patent/PT721467E/en unknown
- 1994-09-26 EP EP94930479A patent/EP0721467B1/en not_active Expired - Lifetime
- 1994-09-26 ES ES94930479T patent/ES2097100T3/en not_active Expired - Lifetime
- 1994-09-26 AU AU79586/94A patent/AU7958694A/en not_active Abandoned
- 1994-09-26 WO PCT/US1994/010867 patent/WO1995009184A1/en active IP Right Grant
- 1994-09-26 DE DE69429664T patent/DE69429664T2/en not_active Expired - Fee Related
- 1994-09-26 AT AT94930479T patent/ATE211920T1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
MACLENNAN A.H.: "The role of the hormone relaxin in human reproduction and pelvic girdle relaxation", SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, vol. 88, 1991, pages 7 - 15 * |
Also Published As
Publication number | Publication date |
---|---|
KR960704933A (en) | 1996-10-09 |
WO1995009184A1 (en) | 1995-04-06 |
ES2097100T1 (en) | 1997-04-01 |
JPH09503208A (en) | 1997-03-31 |
PT721467E (en) | 2002-05-31 |
US5656592A (en) | 1997-08-12 |
EP0721467A1 (en) | 1996-07-17 |
ES2097100T3 (en) | 2002-08-01 |
DE721467T1 (en) | 1997-06-26 |
DE69429664T2 (en) | 2002-08-14 |
DE69429664D1 (en) | 2002-02-21 |
ATE211920T1 (en) | 2002-02-15 |
AU7958694A (en) | 1995-04-18 |
EP0721467A4 (en) | 1998-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6006753A (en) | Use of GLP-1 or analogs to abolish catabolic changes after surgery | |
US6251863B1 (en) | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin | |
Matsumoto | Hormonal therapy of male hypogonadism | |
AU624595B2 (en) | Method for treating and preventing secondary effects of hyperinsulinemia and for treating type 2 diabetes, obesity and hyperlipidemia by application of insulin-like growth factor (IGF I) | |
ES2325777T3 (en) | USE OF GLP-1 OR ANALOGS IN THE TREATMENT OF CEREBROVASCULAR ACCIDENT. | |
US6747006B2 (en) | Use of GLP-1 or analogs in treatment of myocardial infarction | |
EP0721467B1 (en) | Use of relaxin as an analgesic and palliative for intractable pain | |
EP1014885A1 (en) | Method of treating involuntary muscle dysfunction with relaxin hormone | |
Ward et al. | Relaxin increases rat heart rate by a direct action on the cardiac atrium | |
US4654324A (en) | Human proinsulin pharmaceutical formulations | |
US6809079B2 (en) | Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide | |
US4652547A (en) | Pharmaceutical formulations comprising human insulin and human proinsulin | |
US5700775A (en) | Method and treatment composition for decreasing patient time in catabolic state after traumatic injury | |
US20220289812A1 (en) | Elp fusion proteins comprising parathyroid hormone for controlled and sustained release | |
Shaw et al. | Endocrine changes following pituitary desensitization with LHRH agonist and administration of purified FSH to induce follicular maturation | |
Clark et al. | Growth hormone treatment for growth hormone deficient adults | |
Schally et al. | Agonistic Analogs of Growth Hormone-Releasing Hormone: Endocrine and Growth Studies: Growth | |
WO2000013652A2 (en) | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin | |
Deshpande et al. | Periovulatory endocrine profile in Murrah buffaloes under two superovulatory regimes | |
Pinski et al. | Effect of chronic administration of a new potent agonist of GH-RH (1–29) NH2 on linear growth and GH responsiveness in rats | |
Jeevanandam et al. | Growth hormone infusion stimulates lipid mobilization and utilization in parenterally fed trauma victims | |
Wass et al. | The Therapeutic Modulation of Growth Hormone Release | |
VANCE et al. | Growth-hormone-releasing hormone: a clinical update | |
SEKINE et al. | Effects of human growth hormone on lipid metabolism in hypophysectomized rats | |
Stevenson | Calcitonin in the prevention and treatment of osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960429 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE DE ES FR GB IE IT NL PT |
|
ITCL | It: translation for ep claims filed |
Representative=s name: BUGNION S.P.A. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: BA2A Ref document number: 2097100 Country of ref document: ES Kind code of ref document: T1 |
|
EL | Fr: translation of claims filed | ||
TCNL | Nl: translation of patent claims filed | ||
TCAT | At: translation of patent claims filed | ||
DET | De: translation of patent claims | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 19980309 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE DE ES FR GB IE IT NL PT |
|
RHK1 | Main classification (correction) |
Ipc: A61K 38/22 |
|
17Q | First examination report despatched |
Effective date: 20000228 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE DE ES FR GB IE IT NL PT |
|
REF | Corresponds to: |
Ref document number: 211920 Country of ref document: AT Date of ref document: 20020215 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69429664 Country of ref document: DE Date of ref document: 20020221 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20020227 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2097100 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20050829 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20050901 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20050905 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20050919 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20050921 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20050923 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20050927 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20051017 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20051031 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060926 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060926 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060930 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20060930 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070326 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070403 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20070326 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20060926 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20070401 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060926 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20060927 |
|
BERE | Be: lapsed |
Owner name: *SEED JOHN C. Effective date: 20060930 Owner name: *SEED BRIAN Effective date: 20060930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060927 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070926 |